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A B S T R A C T
Breast cancer is a heterogeneous group of diseases determined and distinguished by cellular type, gene expression
and clinical signs and symptoms. Identification of histological and biological markers is of great value in predicting the
progression of tumor growth and anticipating the expected response to various treatment options. Due to a high degree of
cell proliferation in breast tumors and high genetic instability of these tumors, as a consequence of defective DNA repair
mechanisms, chemotherapy as a treatment option often renders very successful results. During our scientific research we
wanted to determine the involvement of the genetic polymorphisms of DNA mismatch repair system (MLH1 gene) and
the subsequent development of breast carcinoma. This study included 108 patients who were surgically treated for inva-
sive breast cancer at the Department of Plastic, Reconstructive and Aesthetic Surgery, University Hospital »Dubrava«.
The expression of the MLH1 gene was determined by immunohistochemical methods. The results showed that 82.9% of
tumor cells expressed the MLH1 gene. Analysis of survival rate for patients with invasive ductal breast cancer showed a
statistically significant (p=0.043) correlation with the expression of MLH1 genes. The overall five year survival rate of
our patients was 78.7%. These results indicate that there is a possible involvement of MLH1 gene in the progression and
development of breast cancer.
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Introduction
Breast carcinoma is the leading cause of cancer re-
lated deaths among women in the entire world. Every
ninth woman can at some point in her lifetime develop
this disease.
Breast carcinoma has a multifactorial etiology where
exogenous and endogenous factors increase the risk of
developing disease. Women in Croatia are at a high risk
of developing breast carcinoma and there is a growing
trend, with an increased number of young females devel-
oping aggressive subtypes when compared to other west-
ern countries. Although there have been many develop-
ments in the diagnosis and treatment of breast carci-
noma, this disease still remains the leading cause of
death in women aged 35 to 591.
Breast carcinoma is the result of abnormal genetic
and epigenetic changes that occur, specifically in the
BRCA and BCRA1 genes2. There are more than 40 genes
that have been shown to be inactive in carcinoma cells in-
cluding the genes responsible for DNA repair, cycle regu-
lation, cell adhesion and cell signalization. These speci-
fied genes serve as potential targets for molecular studies
and therapy opportunities. During replication, DNA po-
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lymerase is responsible for base pair integration and
while this process is prone to errors, incorrectly matched
base pairs are repaired via the mismatch repair system
(MMR). The decreased activity of the MMR protein leads
to a mutated phenotype with an increased degree of
spontaneous mutations. This results in microsatellite in-
stability (MSI) in the repeating mono and di-nucleotide
regions, causing a high percentage of mutated locations,
genome hypervariability, decreased apoptosis and a pre-
disposition for developing breast carcinoma. It has been
proven that in breast carcinoma the gene responsible for
recognizing the mismatched base pairs, MSH2 gene, can
be mutated into many polymorphic variants3.
This research was conducted with the aim to compare
the profile of the MMR gene with patient clinical-patho-
logical status, the degree of hormone receptors and sur-
vival rate. Therefore, patients with breast carcinoma
from Croatia were observed to determine the involve-
ment of the genetic polymorphisms of the MLH1 gene
and the subsequent development of breast carcinoma.
Materials and Methods
This research analyzed the prognostic parameters
and used paraffin preserved biopsies of invasive ductal
breast carcinoma and subsequent lymph node metasta-
sis. 108 female patients were included who were operated
between 1999 and 2002. 18 patients were excluded due to
the lack of biopsy material in the Clinical Hospital Du-
brava in Zagreb, Croatia archive. The majority of the
sample group, 70 patients (77.8%) were from the first
two stages of disease classification. In the first stage
there were 34 patients (37.8%) while in the second there
were 36 (40.0%), in the third stage of disease there were
16 (17.8%) while in the fourth stage only 4 (4.44%) pa-
tients. All the patients were initially surgically treated
with axillary lymph node resection as well. Afterward,
standard adjuvant therapy was indicated and initiated.
In all of the patients, information regarding tumor size,
TNM stage, age, menopausal status, type of adjuvant
therapy used, lymph node status, residual disease, length
of disease remission and overall survival rates were col-
lected. Only patients that complete that statistical infor-
mation were included in the study.
The main ethical committee at the Clinical Hospital
Dubrava in Zagreb, Croatia approved the methods and
research conducted. The conducted procedures were in
accordance with the ethical standards of the institu-
tional, regional, or national committee on human experi-
mentation, and with the Helsinki Declaration of 1975.
The analysis of variance between quantitative vari-
ables such as the degree of differentiation with clinical
and laboratory standards was compared using the ANO-
VA method while qualitative variables were analyzed us-
ing the c²-test.
In order to determine the expression of the MLH1
gene, biopsy samples were analyzed after fixation in 10%
formalin and preserved in paraffin blocks. Afterward, 4
micrometer samples were cut stained with hematoxylin
and eosin and specific MLH1 antigen targeting antibody
was applied. Immunohistochemical detection for estro-
gen and progesterone receptors was applied as well as for
the hMLH receptor. Positive results were identified by
light microscopy as samples which had more than 5% of
the tumor cell stained. In order to determine positive re-
sults, the number of positive immunoreactive cells was
calculated4,5. The degree of MLH1 gene expression is
shown semiquantitativly, (negative (0 cells), slightly posi-
tive (1–50 cells) and positive (>50 cells). Relative degrees
of marker expression are compared with other histo-
logical and clinical factors with relation to overall sur-
vival time and survival time without signs of disease. The
second method of identifying positive samples involved
recognizing the percentage of positive tumor cells in a
sample of 100 cells.
Both methods of cell identification were used for sta-
tistical analysis. In all invasive ductal carcinoma sam-
ples, the degree of histological differentiation (poorly,
medium and well differentiated tumors) and the degree
of local tumor advancement (pathological T and N stage)
was noted. The overall MLH1 gene expression in samples
of invasive ductal carcinoma tissue and lymph node me-
tastasis samples were positively identified based on a
positive reaction of the monoclonal antibody defined by
the manufacturer. The degree of MLH1 molecule expres-
sion in tumor and lymph node samples was compared
with the overall survival time of the patient. The col-
lected data was analyzed and results about the possible
association of MLH1 gene in invasive ductal carcinoma
in Croatian women were documented.
Results
Experimental samples were obtained from female pa-
tients with an average age at diagnosis of 56.1 year. In
this study, a family history of breast carcinoma was posi-
tive in 14 patients (15.6%), and negative in 76 patients
(84.4%). The average size of the tumor in the sample pop-
ulation was 22.7 mm (standard deviation 13,6). All tu-
mors were between 5 and 70 mm. Patients were orga-
nized according to the size as governed by the TNM
classification system; tumors up to 2 cm were found in 53
(58,9%) patients, tumors between 2–5 cm in 35 (38.9%)
patients, and tumors larger than 5 cm in 2 patients
(2.2%). The majority of patients had tumors in the left
breast 59 (65.6%) while 31 (34.4%) patients had a tumor
in the right. Well differentiated tumors were found in 22
patients (24.4%), the majority of the patients 34 patients
(37.8%), had an medium differentiated tumor, while
poorly differentiated tumors were found in 29 (32.2%)
patients. 5 patients (5.6%) out of the original sample
lacked sufficient data needed and were not included.
Lymphovascular invasion was documented in 10 patients
(11.1%), while the majority of the patients (88.9%) lacked
lymphovascular invasion at the time of initial diagnosis.
In 87 (96.7%) patients, the tumor did not posses an area
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of necrosis. The majority of the patients (54.4%) did not
have lymph node involvement at the time of diagnosis, 24
patients (26.7%) had between 1–3 positive nodes (N1
stage), 10 patients (11.1%) had between 3–10 positive
nodes (N2 stage) and more than 10 positive nodes (N3
stage) were found in 7 patients (7.8%). Distant metasta-
ses were found in 4 patients (4.4%). 35 patients (38.9%)
had estrogen receptor negative disease while the rest
were positive with variable degrees of intensity and per-
centage according to their H-score. 44 (48.9%) patients
were progesterone receptor negative.
Patients with breast carcinoma were treated with sur-
gery, adjuvant cytostatic, hormonal and/or radiotherapy
according to the stage of the disease and steroid receptor
status. Tamoxifen as an adjuvant therapy was given to
53 (58.9%) patients while the rest, 35 (38.9%) were not
treated with adjuvant hormonal therapy. 76 (84.4%) re-
ceived some other form of adjuvant chemotherapy while
13 patients did not. One patient did not have the docu-
mentation of which therapy they had received. In the
sample group, 57 patients (63.3%) were treated with ra-
diotherapy while 32 (35.6%) were not. Out of the entire
sample group, only 8 (8.9%) patients relapsed with dis-
ease.
The average percentage of positive immunoreactive
tumor cells was found to be 82.9% (standard deviation
24.0 while results ranged between 0% (1 patient) and
100% (Figure 1))
The majority of tumor samples were found to posses
MLH1 gene with 70–100% of the cells staining postive.
The degree of staining intensity was classified into 4
groups (Table 1: Figures 2, 3, 4 and 5). One sample was
immunohistochemically negative, 20% weakly stained
(category 1), while the rest of the samples stained be-
tween medium (category 2) and high intensity (category
3) for the MLH1 gene. Figures 2, 3, 4 and 5 display the
various immunohistochemical intensities in biopsy sam-
ples when stained for the MLH1 gene.
When the patients were observed in regards to age
and histological tumor grade, it was found the average
age of patients with low grade carcinomas was 60.86
years, for medium differentiated tumors (grade 2) was
56.6 years while patients with poorly differentiated (sta-
ge 3) tumors was 54.69. In patients with medium differ-
entiated tumors at the time of initial diagnosis, the most
frequent carcinoma grade was found to be grade 1 (16 pa-
tients), while only 5 patients with poorly differentiated
tumors was found to be in the first stage. Well differenti-
ated tumors in stage 1 were observed in 9 patients. The
majority of patients in the third stage of disease (n=10)
were found to have poorly differentiated tumors. Estro-
gen receptors were not detected in poorly differentiated
tumors. The highest degree of MLH1 positive tumors
were seen in the medium differentiated tumor group.
Results indicate that there is no significant statistical
relevance between the expressions of MLH1 gene with
prognostic factors such as: size of tumor, lymph node in-
volvement, or positive steroid receptors, nor with any
clinical and pathohistological signs such as age, size of
the tumor, distant metastasis, stage of disease, lympho-
vascular invasion or with tumor necrosis. There was a re-
lationship between the expressions of the MLH1 gene
with the histological grade of tumors (Figure 6).
When the percentage immunoreactive cells were com-
pared with the tumor differentiation, there was no statis-
tical significance. (Kruskal-Wallis test, H=4.96; p=
0.084).
When the relationship between prognostic factors and
the relapse of disease were compared, there was no corre-
lation between the relapse of disease and age, lymph
node involvement, stage of differentiation, presence of
estrogen or progesterone receptors, adjuvant chemother-
apy and adjuvant hormonal therapy. There was a positive
correlation between disease relapse and the size of the
original tumor.
In the sample group, the overall 5 year survival rate
was 78.7%, with 75% of these patients without any re-
lapse of disease. The disease free survival period was cal-
culated as the time from initial diagnosis until the re-
lapse of disease in months. It has been found that the
overall survival rate is related to the size of the tumor
(p=0.004), involvement of axillary lymph nodes (p=
0.018), the presence of distant metastasis (p=0.036) and
the stage of disease (p=0.001). All other factors observed
were not statistically significant when compared with
the overall survival rate. Analysis of the overall survival
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TABLE 1
VARIOUS DEGREES OF STAINING INTENSITY IN BIOPSY
SAMPLES





Fig. 1. Number of patients and the percentage of tumor cells with
a positive expression for MLH1 gene
rate in patients with invasive ductal carcinoma of the
breast was statistically related to the expression of the
MLH1 gene in tumor cells (p=0.043) (Figure 7). There is
a statistically significant relationship in survival rates
when depending on the pT stage (p=0.003).
There was a statistically significant relationship be-
tween the overall survival rate and the presence of dis-
tant metastasis (p=0.006). When comparing patients
with and without metastasis, it was found that patients
who did not have distant metastasis statistically had a
longer survival period. There was a significant difference
in the overall survival rate between the various stages of
disease (p=0.001). The 5 year survival rate in the first
stage of disease was 90% while in the fourth stage was
only 25%. It is important to note that the majority of
stage 4 patients die within 20 months of diagnosis.
Discussion
The majority of authors agree that the successful
treatment of breast carcinoma is dependent on early di-
agnosis and that a tumor smaller than 1 cm in the major-
ity of cases is curable. There are many authors who state
that breast carcinoma from the start is a systemic dis-
ease6,7. Support of this theory can be seen with the vari-
able biological behavior of breast cancer, especially the
invasive ductal carcinoma which is the most frequently
seen. Due to this variability, the difficulty in treating this
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Fig. 2. Negative reaction for MLH1 (MLH1 x 100)
Figs. 2, 3, 4 and 5 display the various immunohistochemical intensities in biopsy samples when stained for the MLH1 gene
Fig. 3. Weak reaction for MLH1 (MLH1 x 200)
Fig. 4. Average intensity for MLH1 (MLH1x200) Fig. 5. Strong reaction for MLH1 (MLH1 x 200)
disease can be understood because of the unfamiliarity
with this type of tumor. Invasive ductal carcinoma is
therefore the focus of a variety of different studies7,8.
With the development of new medications such as
cytostatic, the treatment of this disease is becoming
more successful; although there are still numerous asso-
ciated side effects. It is therefore extremely important to
recognize which patients will have the greatest benefit of
medication therapy and to minimize the side effects as
much as possible9,10. The progression of disease can be
foreseen using the many known signs and symptoms at
the time of diagnosis. These include the size of the tumor,
the involvement of axillary lymph nodes and the hor-
monal receptor status 11. These factors directly influence
the choice of therapy and it is necessary to identify which
patients are at a high risk of developing secondary di-
sease12.
Research results show that patients with better dif-
ferentiated tumors most often had smaller tumors (p<
0.019), lower number of lymph nodes with metastasis
(p<0.027), and more often had estrogen receptor positive
tumors (p=0.008). These results coincide with other lit-
erature findings13.
Our research failed to show a statistically significant
correlation between survival rate and tumor grade which
may possible be due to the analysis of patients with dif-
ferent tumor sizes and at various stages of lymph node
involvement.
Our research show the relationship between the size
of the tumor and the survival rate (p=0.004) as well as
lymph node involvement and survival rate (p=0.018).
These results are similar to other studies which show
that tumor size is an important prognostic factor13. Car-
ter et al. analyzed 24740 patients with a tumor size
smaller than 1 cm and found that 99% had a 5 year sur-
vival period while patients with a tumor between 1 and 3
cm, only 89% survived 5 years14. Lymph node involve-
ment has also been found to be an important prognostic
factor for survival as patients with lymph node metasta-
sis had a lower survival rate which concurs with multiple
foreign studies.
In 12 patients with invasive ductal carcinoma of the
breast, 83% were found to have microsatellite instability
regions in the associated gene which indicates the strong
possibility of MMR in the development of breast carci-
noma 15. Results show that the MLH1 gene may possibly
be used for the prognosis of disease and the possible op-
portunity for use in clinical practice. A lower degree of
gene expression of the MLH1 gene was more common in
carcinomas with distant metastasis as well as in larger
tumors (larger than 3cm.). There was a correlation with
the expression of MLH1 gene with the grade of the tu-
mor, an important prognostic factor and therefore the
MLH1 gene could also be used as a prognostic factor.
The study conducted by Sondes Karray-Chouayekh
showed that tumors which were estrogen receptor nega-
tive were more malignant with less MLH1 methyla-
tions16. Our results also correlated with Layfield, who
showed a relationship with positive hormone receptors
and a lower tumor grade with a longer survival rate17.
Using immunohistochemical methods with MLH1 an-
tibody, we intended to show the relationship between
mismatched based pairs with other clinical-pathological
factors in breast carcinoma. Quantitatively, gene involve-
ment and the presence of protein products in the repair
of mismatched bases were observed18,19. Our goal was to
determine the various MLH1 expressions and compare
them with the other parameters associated with breast
carcinoma.
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Fig. 6. The percentage of MLH1 gene expression in tumors of var-
ious differentiations
Fig. 7. Survival rates and the expression of MLH1 gene in breast
cancer patients
It is well known that mutations within our genome
are a constant occurrence and are most easily seen in
base pairs which repeat (microsatellite regions). This oc-
currence of micro- satellite instability has been found in
breast tumors by Chintamani, and Murata20,21.
In order to determine the lack of MMR gene activity
we tested the expression of the MMR gene protein prod-
uct histochemically. The role of the MMR gene in breast
carcinoma has been the focus of study for the last 20
years. It was found that the presence of MSI varies be-
tween 5–30% in certain studies and that it can be used as
a determining factor for breast carcinoma. Murata and
Mackay, observed 7 microsatellite regions within 20
breast carcinoma types and found variations in about
20% while Patel et al. found variations in microsatellite
regions in about 85%21,22,24. It is therefore necessary to
determine the correlation between tumor markers and
repair methods in invasive ductal carcinomas. It can be
concluded that the immunohistochemically observed
MMR protein is a good test for genetic MMR dysfunction
in breast carcinomas21,22. In the future surgery option
this can also lead to the right choice of breast reconstruc-
tion method23.
Our research agrees with the research conducted by
Chintamania where no significant correlation was found
between the expression of MLH1 gene and the age of the
patient when diagnosed. Likewise we have observed sim-
ilarities as with some authors about the correlation be-
tween the MLH1 gene expression and the histologic
grade of the tumor25. We observed that the gene expres-
sion and the tumor grade are inversely proportional,
without statistical significance.
In one study by Ahn Byugg, 71 histological slides of
stage II and stage III tumors was observed and a positive
expression of MLH1 was found in 57.7% of cases26. Those
patients with advanced disease, axillary lymph node in-
volvement and with little expression of MLH1 had a
weaker response to chemotherapy than those patients
with a high degree of expression27. In breast carcinoma it
was found that there is a loss of heterozygocity of the
MLH1 gene in 46% of sporadic tumors. Khilko et al.
(since 2007) have followed 121 patients with breast carci-
noma and failed to show a loss of MLH1 expression in
ever the entire patient group regardless of the various
pathological and clinical signs . They have therefore con-
cluded that this gene does not play a role in the develop-
ment of breast carcinoma.
Luqman et al. have found MSI in up to 64% out of 108
patients located on the A25 microsatellite region28. Or-
landi et al. and Molist have not observed the presence of
MSI in a series of 84, 267, 40 and 29 breast carcinomas
respectably29,30. They have all concluded that MSI is not
common in breast tumors. Batistaton et al. has also
failed to show the loss of MLH1 expression in 40 breast
carcinoma samples31.
A large percentage of authors state that these MMR
genes are not important factors in the development of
breast tumors, although they all agree the need for fur-
ther research. Soudes, Karray et al. (since 2009.) have
analyzed 74 patients with breast tumors and have shown
the expression of MLH1 in 24.3% of samples16. They
found a connection between MLH1 and the size of the tu-
mor and have concluded that this gene facilitates tumor
cell invasion. They also state that MLH1 gene is found in
advanced metastatic disease. They found that 14.3% of
their patients were in the T3 or T4 stage as compared to
4.8% in T1 or T2 stages, although this difference was not
statistically significant. (p=0.27). There is a positive re-
lationship between the efficacy of therapy and MLH1 ex-
pression (p=0.004). When the survival rates were ob-
served in 34 patients in the period of 3–119 months, it
was found that the expression of MLH1 can be a signifi-
cant prognostic factor for breast carcinoma.
In their study, Kostera F. et al. found that out of 200
patients with breast carcinoma, MLH1 expression was
positive in 86.5%, which is concurrent with our results of
over 80% positive results19. There is a sign that the vari-
ability in microsatellite regions in breast cancer is differ-
ent from that in colorectal carcinoma32.
Conclusion
The primary conclusion of this research is that the
lowered expression of the MLH1 gene is rare in sporadic
breast carcinomas, while the second conclusion is that
the mutation of the gene responsible for base pair repair
can be a secondary occurrence in the progression of
breast carcinoma. The results in this study are similar to
the results obtained by other authors who used similar
methodology. Therefore, in this study, MLH1 was
positive in 73 (80.22%) and negative in 17 (19.78%)
patients. This discussion signifies the need for further
research in order to determine the involvement of the
genetic polymorphisms of DNA mismatch repair system
(MLH1 gene) and the subsequent development of breast
carcinoma, which is the most common malignant tumor
in woman and whose incidence and mortality rate, is
constantly increasing.
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EKSPRESIJA GENA ODGOVORNIH ZA POPRAVAK KRIVO SPARENIH BAZA U
MOLEKULI DNA (MLH1) KOD INVAZIVNOG DUKTALNOG KARCINOMA DOJKE
S A @ E T A K
Rak dojke je heterogena skupina bolesti koju definiramo tipom zahva}enih stanica i gena, te razli~itom klini~kom
slikom. Identifikacija histolo{kih i biolo{kih markera od velike je va`nosti u predvi|anju progresije rasta tumora i
odgovora na razli~ite modalitete lije~enja. Zbog visokog stupnja proliferacije stanica kod karcinoma dojke i visoke ge-
netske nestabilnosti tih tumora, kao posljedica neispravnog mehanizmima popravka DNA molekule, kemoterapijom se
posti`u uspje{ni rezultati lije~enja. Tijekom na{eg znanstvenog istra`ivanja `eljeli smo utvrditi stupanj genetskih poli-
morfizama kod gena koji su odgovorni za mehanizam ispravljanja krivo sparenih baza u molekuli DNA (MLH1 gena) i
naknadnog razvoja raka dojke. Ovo istra`ivanje uklju~uje 108 pacijentica koje su kirur{ki lije~ene zbog invazivnog raka
dojke na Klinici za plasti~nu, rekonstrukcijsku i estetsku kirurgiju, KB »Dubrava«. Ekspresija MLH1 gena je odre|ena
imunohistokemijskim metodama. Rezultati su pokazali da je 82,9% tumorskih stanica imalo ekspresiju MLH1 gen.
Analiza pre`ivljenja bolesnica s duktalnim invazivnim karcinomom dojke je pokazala statisti~ki zna~ajnu (p=0,043)
korelaciju s ekspresijom gena MLH1. Ukupna petogodi{nja stopa pre`ivljena na{ih pacijenata bila je 78,7%. Rezultati
potvr|uju prisutnost MLH1 gena te njihovu uklju~enost u progresiju i razvoj raka dojke.
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